ChemoCentryx Stock News

Here is how ChemoCentryx (CCXI) and Eiger BioPharmaceuticals (EIGR) have performed compared to their sector so far this year.

Cancer-drug maker Amgen solidified its position in a highly competitive market by acquiring its rival Mirati Therapeutics.

ChemoCentryx (CCXI) reported earnings 30 days ago. What's next for the stock?

Does ChemoCentryx (CCXI) have what it takes to be a top stock pick for momentum investors? Let's find out.

Pfizer Inc.'s PFE, +0.24% $5.4 billion acquisition of Global Blood Therapeutics Inc. GBT, +0.02% is the latest sign that cash-flush drug makers are ready to jump back into dealmaking.

SAN CARLOS, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the cancellation of its second quarter 2022 financial results conference call scheduled for Tu

ChemoCentryx (CCXI) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

On Thursday, shares of ChemoCentryx Inc. ( CCXI , Financial) shot up more than 110% before closing the day at $50.43 on the news that the small-cap biotech company has entered into an agreement to be

Shares of ChemoCentryx, Inc. (NASDAQ: CCXI) are skyrocketing Thursday following a groundbreaking announcement for the biopharmaceutical company. Why Is It Moving?

Source: Shutterstock ChemoCentryx (NASDAQ: CCXI ) stock is rocketing higher on Thursday as investors react to news of an acquisition deal with Amgen (NASDAQ: AMGN ). This deal has Amgen agreeing to ac

Amgen (AMGN) is buying ChemoCentryx (CCXI) for $4 billion in cash. These are the details.

The rare-disease specialist is being bought out at a sizable premium.

Amgen Inc. AMGN, +1.32% said Thursday it plans to buy ChemoCentryx Inc. CCXI, +3.61% for $3.7 billion in cash. The deal will give Amgen access to Tavneos, a treatment for ANCA-associated vasculitis th

SAN CARLOS, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's second quarter 2022 financial results will be released after market close o

ChemoCentryx (CCXI) has only one product approved for sale in its portfolio, Tavneos. Nevertheless, it is progressing well with the clinical development of its pipeline candidates.